Reexamining misconceptions about β-blockers in patients with diabetes

Clinical Diabetes

Volumn 27, Issue 1, 2009, Pages 36-46

  McGill, Janet B ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; METOPROLOL; METOPROLOL TARTRATE; NEBIVOLOL; PRAVASTATIN; PROPRANOLOL; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DIZZINESS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATALITY; FATIGUE; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MEDICAL CARE; MICROALBUMINURIA; MICROANGIOPATHY; PATIENT COMPLIANCE; POPULATION DISTRIBUTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK MANAGEMENT; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 59349095051     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.27.1.36     Document Type: Review

References (68)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y: Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115:e69-e171, 2007
2. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 26 (Suppl. 1):S80-S82, 2003
3. Makrilakis K, Bakris G: Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol 31 (Suppl. 2):S34-S40, 1998
4. National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes. Hypertension 23:145-158; discussion 159-160, 1994
5. AACE Hypertension Task Force: American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hypertension. Endocr Pract 12:193-222, 2006
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
7. U.K. Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
8. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
9. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
11. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. Circulation 112:e154-e235, 2005
12. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886-1892, 1996
13. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684, 1999
14. Fonarow GC: Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes. Am J Cardiol 93:77B-81B, 2004
15. Tse WY, Kendall M: Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 11:137-144, 1994
16. Bell DS: Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade. Curr Med Res Opin 21:1191-1200, 2005
17. Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO: Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 10:1525-1530, 1992
18. Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203-209, 1991
19. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice? Lancet 364:1684-1689, 2004
20. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 14:489-494, 1996
21. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21:1563-1574, 2003
22. Sarafidis PA, Bakris GL: Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich) 8:351-356; quiz 357-358, 2006
23. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895-906, 2005
24. Messerli FH, Grossman E: Beta-blockers in hypertension: is carvedilol different? Am J Cardiol 93:7B-12B, 2004
25. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M, Mikhailidis DP: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 8:127-134, 2003
26. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227-2236, 2004
27. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities:the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374-381, 1996
28. Haenni A, Lithell H: Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 43:455-461, 1994
29. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322:15-18, 2001
30. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
31. Colagiuri S, Cull CA, Holman RR: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UKPDS 61. Diabetes Care 25:1410-1417, 2002
32. McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS: Beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab 9:408-417, 2007
33. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr, Waterhouse B, Lukas MA, Anderson KM, Bell DS: Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
34. DCCT Research Group: Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 18:1415-1427, 1995
35. Barnett AH, Leslie D, Watkins PJ: Can insulin-treated diabetics be given beta-adrenergic blocking drugs? BMJ 280:976-978, 1980
36. Thamer M, Ray NF, Taylor T: Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 21:1387-1400, 1999
37. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278:40-43, 1997
38. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A: Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345:1195-1198, 1995
39. McMurray J, Fraser DM: Captopril, enalapril, and blood glucose [Letter]. Lancet 1:1035, 1986
40. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P: Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 89:811-813, 1990
41. Sawicki PT, Siebenhofer A: Betablocker treatment in diabetes mellitus. J Intern Med 250:11-17, 2001
42. Borch-Johnsen K, Helweg-Larsen K: Sudden death and human insulin: is there a link? Diabet Med 10:255-259, 1993
43. Sartor G, Dahlquist G: Short-term mortality in childhood onset insulin-dependent diabetes mellitus: a high frequency of unexpected deaths in bed. Diabet Med 12:607-611, 1995
44. Tattersall RB, Gill GV: Unexplained deaths of type 1 diabetic patients. Diabet Med 8:49-58, 1991
45. Thordarson H, Sovik O: Dead in bed syndrome in young diabetic patients in Norway. Diabet Med 12:782-787, 1995
46. Ziegler D: Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 10:339-383, 1994
47. Lee SP, Yeoh L, Harris ND, Davies CM, Robinson RT, Leathard A, Newman C, Macdonald IA, Heller SR: Influence of autonomic neuropathy on QTc interval lengthening during hypoglycemia in type 1 diabetes. Diabetes 53:1535-1542, 2004
48. Lee SP, Harris ND, Robinson RT, Davies C, Ireland R, Macdonald IA, Heller SR: Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes. Diabetologia 48:1269-1272, 2005
49. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT Jr, Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, Bakris GL: Body weight changes with beta-blocker use: results from GEMINI. Am J Med 120:610-615, 2007
50. American Diabetes Association: Standards of medical care in diabetes - 2008. Diabetes Care 31 (Suppl. 1):S12-S54, 2008
51. Saydah S, Cowie C, Eberhardt MS, De Rekeneire N, Narayan KM: Race and ethnic differences in glycemic control among adults with diagnosed diabetes in the United States. Ethn Dis 17:529-535, 2007
52. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS: Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 167:2431-2436, 2007
53. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49:69-75, 2007
54. Grant RW, Devita NG, Singer DE, Meigs JB: Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 26:1408-1412, 2003
55. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
56. Johnson ML, Pietz K, Battleman DS, Beyth RJ: Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 10:926-932, 2004
57. Steiner G: A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? Treat Endocrinol 4:311-317, 2005
58. Munger MA, Van Tassell BW, LaFleur J: Medication nonadherence: an unrecognized cardiovascular risk factor [article online]. MedGenMed 9:58, 2007. Available from http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool= pubmed&pubmedid=18092064. Accessed 11 December 2008
59. Borrild NJ: Patients' experiences of antihypertensive drugs in routine use: results of a Danish general practice survey. Blood Press Suppl 1:23-25, 1997
60. Leenen FH: Intermittent blood pressure control: potential consequences for outcome. Can J Cardiol 15:13C-18C, 1999
61. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310, 2001
62. Lasater M: The effect of a nurse-managed CHF clinic on patient readmission and length of stay. Home Healthc Nurse 14:351-356, 1996
63. Ni H, Nauman D, Burgess D, Wise K, Crispell K, Hershberger RE: Factors influencing knowledge of and adherence to self-care among patients with heart failure. Arch Intern Med 159:1613-1619, 1999
64. Kogut SJ, Andrade SE, Willey C, Larrat EP: Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol Drug Saf 13:591-598, 2004
65. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS: Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease [article online]. BMC Cardiovasc Disord 6:48, 2006. Available from http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool= pubmed&pubmedid=17173679. Accessed 11 December 2008
66. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL: Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol 98:32L-38L, 2006
67. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA: Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich) 8:840-849, 2006
68. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004